Glaxo smith Kenya( GSK) exited Kenya after decades of manufacturing drugs in Kenya due to changing micro and macro environment that pushed the company away following influx of drugs from other countries.
Speaking during the national validation workshop on the social health insurance regulations 2024 and regulatory impact statement held at the Kenyatta International convention center ( KICC) vice president of psk Dr Joseph Kathare has said the price of GSK drugs have since doubled since the exit of the company from the kenyan market a move that could have been cushioned by government interventions to enable the giant drug company stay afloat.
